Search

Your search keyword '"Guigay, Joël"' showing total 167 results
Start Over Author "Guigay, Joël" Language english
167 results on '"Guigay, Joël"'

1. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

Author

Guigay, Joël, Le Caer, Hervé, Ferrand, François-Régis, Geoffrois, Lionel, Saada-Bouzid, Esma, Fayette, Jérôme, Sire, Christian, Cupissol, Didier, Blot, Emmanuel, Guillet, Pierre, Pavillet, Julien, Bozec, Laurence, Capitain, Olivier, Rolland, Frédéric, Debourdeau, Philippe, Pointreau, Yoann, Falandry, Claire, Lopez, Stéphane, Coutte, Alexandre, Chatellier, Thierry, Dalloz, Pierre, Ortholan, Cécile, Michel, Cécile, Lacas, Benjamin, Cheurfa, Nadir, Schwob, Dominique, Bourhis, Jean, Mertens, Cécile, and Aupérin, Anne

Published
2024
Full Text
View/download PDF

2. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

Author

Guigay, Joël, Ortholan, Cécile, Vansteene, Damien, Cupissol, Didier, Even, Caroline, Kaminsky, Marie-Christine, Sire, Christian, Blot, Emmanuel, Debourdeau, Philippe, Bozec, Laurence, Saada-Bouzid, Esma, Fayette, Jérôme, Dalloz, Pierre, Pointreau, Yoann, Caer, Hervé Le, Falandry, Claire, Digue, Laurence, Braccini, Antoine, Lopez, Stéphane, Guillet, Pierre, Michel, Cécile, Cheurfa, Nadir, Schwob, Dominique, Bourhis, Jean, Mertens, Cécile, and Aupérin, Anne

Published
2024
Full Text
View/download PDF

3. Integrating artificial intelligence into lung cancer screening: a randomised controlled trial protocol

Author

Paul Hofman, Sylvie Leroy, Jonathan Benzaquen, Bernard Padovani, Charles Hugo Marquette, Fontas Eric, Eric Fontas, Stephanie Lopez, Nesrine Rouis, Jacques Boutros, Allegra Maryline, Amamou-Elhani Faten, ARFI Thierry, Baque Jean, Baque-Juston Marie, Barel Remy, Barrios Baretto Deisy, Baudin Guillaume, Beck Camille, Bellmann Laurent, Benchetrit Maxime, Benkirane Mohamed-Taib, Benyoussef Sid Ali, Benzaquen Jonathan, Berthet Jean Philippe, Bonnard Eric, Bordone Olivier, Boutros Jacques, Boyer Guy-René, Bulsei Julie, Caillon Cynthia, Castelnau Olivier, Chalmin Jérémy, Chebib Ralph, Cohen Charlotte, Cruzel Coralie, Degoutte Aurélien, Delin Margot, Diascorn Yann, Doux Nathalie, Durand Lorraine, Duval Yannick, El Hemweh Omar, Fayada Julien, Felderhoof Eric, Feliciello Stéphane:, Femenia Richard, Ferrari Victoria, Francisci Marc Paul, Ghalloussi Hannah, Gomez-Caro-Andres Abel, Gora Assia, Griffonnet Jennifer, Gubeno Marie Christine, Guigay Joël, Hamila Marame, Harrathi Mohamed-Ali, Henaut Quentin, Herin Edouard, Hofman Paul, Hofman Véronique, ILIE Marius, Korzeniewski Sylvia, Lalvee Salomé, Lassalle Sandra, Le Heron Charles, Leray Loïc, Leriche Julien, Lerousseau Lionel, Leroy Sylvie, Lespinet Fabre Virginie, Lestrez Roxane, Leyssalle Axelle, Long Mira Elodie, Lopez Stephanie, Mahler Valentin, Maniel Charlotte, Marcano Xavier, Marco Roucayrol Sabine, Marquette Charles-Hugo, Martin Nicolas, Mistri Aurélie, Nicolle Isabelle, Novellas Sébastien, Oddo Frédéric, Otto Josiane, Padovani Bernard, PERQUIS Marie Pierre, Philibert Lorène, Pop Daniel, Pottier Héloïse, Raguin Olivier, Rolland Fabien, Rouis Nesrine, Rousset Johanna, Ruitort Frédéric, Sanfiorenzo Céline, Selva Eric, Tanga Virginie, Tardy Magalie, Thomas Olivier, Varenio Sophie, Verdoire Paul, Vigny Isabelle, Washetine Kévin, Zurlinden Olivier, Tarhini Adam, and Perrotin Cédric

Subjects
Medicine
Abstract

Introduction Lung cancer (LC) is the most common cause of cancer-related deaths worldwide. Its early detection can be achieved with a CT scan. Two large randomised trials proved the efficacy of low-dose CT (LDCT)-based lung cancer screening (LCS) in high-risk populations. The decrease in specific mortality is 20%–25%.Nonetheless, implementing LCS on a large scale faces obstacles due to the low number of thoracic radiologists and CT scans available for the eligible population and the high frequency of false-positive screening results and the long period of indeterminacy of nodules that can reach up to 24 months, which is a source of prolonged anxiety and multiple costly examinations with possible side effects.Deep learning, an artificial intelligence solution has shown promising results in retrospective trials detecting lung nodules and characterising them. However, until now no prospective studies have demonstrated their importance in a real-life setting.Methods and analysis This open-label randomised controlled study focuses on LCS for patients aged 50–80 years, who smoked more than 20 pack-years, whether active or quit smoking less than 15 years ago. Its objective is to determine whether assisting a multidisciplinary team (MDT) with a 3D convolutional network-based analysis of screening chest CT scans accelerates the definitive classification of nodules into malignant or benign. 2722 patients will be included with the aim to demonstrate a 3-month reduction in the delay between lung nodule detection and its definitive classification into benign or malignant.Ethics and dissemination The sponsor of this study is the University Hospital of Nice. The study was approved for France by the ethical committee CPP (Comités de Protection des Personnes) Sud-Ouest et outre-mer III (No. 2022-A01543-40) and the Agence Nationale du Medicament et des produits de Santé (Ministry of Health) in December 2023. The findings of the trial will be disseminated through peer-reviewed journals and national and international conference presentations.Trial registration number NCT05704920.

Published
2024
Full Text
View/download PDF

4. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Author

Galot, Rachel, Le Tourneau, Christophe, Saada-Bouzid, Esma, Daste, Amaury, Even, Caroline, Debruyne, Philip, Henry, Stéphanie, Zanetta, Sylvie, Rutten, Anemie, Licitra, Lisa, Canon, Jean-Luc, Kaminsky, Marie-Christine, Specenier, Pol, Rottey, Sylvie, Guigay, Joël, Kong, Anthony, Tinhofer, Inge, Borcoman, Edith, Dirix, Lieve, Raveloarivahy, Tiana, Fortpied, Catherine, Vanlancker, Maureen, Morfouace, Marie, Govaerts, Anne-Sophie, and Machiels, Jean-Pascal

Published
2021
Full Text
View/download PDF

6. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

BABA-HAMED, Nabil, BABIN, Emmanuel, BERA, Guillaume, BETRIAN-LAGARDE, Sarah, BLOT, Emmanuel, BOMPAS, Emmanuelle, BOREL, Christian, BOUCHEKOUA, Mohamed, BOZEC LE MOAL, Laurence, BRUYAS, Amandine, CALAIS, Gilles, CARPIUC, Ioana, CHAPET, Sophie, CHATELLIER, Thierry, CHAUFFERT, Bruno, CHELI, Sandrine, CLATOT, Florian, COJOCARASU, Oana, CORNELLY, Alexandre, COUTTE, Alexandre, DALLOZ, Pierre, DARLOY, Franck, DELHOMMEAU, Melissa, DE RAUCOURT, Dominique, DEBELLEIX, Christophe, DEBOURDEAU, Philippe, DILLIES-LEGRAIN, Anne Françoise, DO, Pascal, DUBOS-ARVIS, Catherine, DUCOULOMBIER, Agnès, EL KOURI, Claude, FALKOWSKI, Sabrina, FERRAND, François-Regis, GATINEAU, Michel, GERVAIS, Radj, GRAS, Louis, GUILLET, Pierre, HASBINI, Ali, HENAULT, Stéphane, HERRERA GOMEZ, Ruth Gabriela, HUGUET, Florence, KAMINSKY, Marie Christine, LAGRANGE, Aurélie, LAVAU-DENES, Sandrine, LE CAER, Hervé, LE FOLL, Christine, LEFEBVRE, Gautier, LINOT, Benjamin, LOPEZ, Qian, LORTHOLARY, Alain, MATIAS, Margarida, MAYACHE-BADIS, Lamia, MINNE, Floriane, MOLLON, Delphine, NEIDHARDT, Eve Marie, PAVILLET, Julien, PEYRADE, Frédéric, POINTREAU, Yohann, RAMEE, Jean-François, RAUCHE, Camille, RICHARD, Sandrine, RIZZO, Claudia, ROLLAND, Frédéric, SCHLURMANN, Friderike, STEFANI, Laetitia, TASSY, Louis, TAZI, Youssef, THERY, Jean-Christophe, TORTI EL ZEIN, Florida, TOULLEC, Clémence, TOURANI, Jean-Marc, TOUSSAINT, Philippe, VANBOCKSTAEL, Julie, VAULEON, Elodie, VIRET, Frédéric, WALER, Sabine, ATZPODIEN, Jens, BEHRENS, Caecilia, BUSCH, Chia Jung, DIETZ, Andreas, FELDMANN, Georg, FIETKAU, Rainer, GRANIZKA, Thordis, GREWE, Jürgen, GUNTINAS-LICHINUS, Orlando, HADLER-MIKESCH, Kristina, HAHN, Dennis, INHESTERN, Johanna, KELLNER, Karolin, KLINGHAMMER, Konrad, KRONENBERGER, Roland, LUEDTKE-HECKENKAMP, Kerstin, OCHSENREITHER, Sebastian, OTREMBA, Burkhard, PEUKER, Caroline Anna, PIRLICH, Markus, ROTHMANN, Frank, TOMETTEN, Mareike, WOHLFARTH, Sabine, ZEBRALLA, Veit, ZIPFEL, Matthias, ADANSA KLEIN, Juan Carlos, ARRAZUBI, Virginia, CABALLERO DAROQUI, Javier, CASTELO, Beatriz, CIRAUQUI CIRAUQUI, Beatriz, CRUZ HERNANDEZ, Juan Jesus, GALLEGO, Oscar, IGLESIAS DOCAMPO, Lara Carmen, LOPEZ POUSA, Antonio, MARTINEZ DEL PRADO, Maria, MARTINEZ-TRUFERO, Javier, PASTOR BORGONON, Miguel, PEREZ RUIZ, Elisabeth, QUIROGA GARCIA, Vanesa, RUBIO CASADEVALL, Jordi, VAZQUEZ FERNANDEZ, Silvia, Guigay, Joël, Aupérin, Anne, Fayette, Jérôme, Saada-Bouzid, Esma, Lafond, Cédrik, Taberna, Miren, Geoffrois, Lionnel, Martin, Laurent, Capitain, Olivier, Cupissol, Didier, Castanie, Hélène, Vansteene, Damien, Schafhausen, Philippe, Johnson, Alison, Even, Caroline, Sire, Christian, Duplomb, Sophie, Evrard, Camille, Delord, Jean-Pierre, Laguerre, Brigitte, Zanetta, Sylvie, Chevassus-Clément, Cécile, Fraslin, Aldéric, Louat, Fanny, Sinigaglia, Laura, Keilholz, Ulrich, Bourhis, Jean, and Mesia, Ricard

Published
2021
Full Text
View/download PDF

7. Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Author

Tao, Yungan, Aupérin, Anne, Sun, Xushan, Sire, Christian, Martin, Laurent, Coutte, Alexandre, Lafond, Cedrik, Miroir, Jessica, Liem, Xavier, Rolland, Frederic, Even, Caroline, Nguyen, France, Saada, Esma, Maillard, Aline, Colin-Batailhou, Natacha, Thariat, Juliette, Guigay, Joël, and Bourhis, Jean

Published
2020
Full Text
View/download PDF

10. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial

Author

Haddad, Robert, Guigay, Joel, Keilholz, Ulrich, Clement, Paul M., Fayette, Jérôme, de Souza Viana, Luciano, Rolland, Frédéric, Cupissol, Didier, Geoffrois, Lionnel, Kornek, Gabriela, Licitra, Lisa, Melichar, Bohuslav, Ribaldo Nicolau, Ulisses, Rauch, Daniel, Zanetta-Devauges, Sylvie, Cohen, Ezra E.W., Machiels, Jean-Pascal, Tahara, Makoto, Vermorken, Jan, Geng, Yuan, Zografos, Eleftherios, and Gauler, Thomas

Published
2019
Full Text
View/download PDF

14. Predicting early death in older adults with cancer

Author

Boulahssass, Rabia, Gonfrier, Sebastien, Ferrero, Jean-Marc, Sanchez, Marine, Mari, Véronique, Moranne, Olivier, Rambaud, Cyrielle, Auben, Francine, Hannoun levi, Jean-Michel, Bereder, Jean-Marc, Bereder, Isabelle, Baque, Patrick, Turpin, Jean Michel, Frin, Anne-Claire, Ouvrier, Delphine, Borchiellini, Delphine, Largillier, Remy, Sacco, Guillaume, Delotte, Jerome, Arlaud, Cyprien, Benchimol, Daniel, Durand, Matthieu, Evesque, Ludovic, Mahamat, Abakar, Poissonnet, Gilles, Mouroux, Jérôme, Barriere, Jérôme, Benizri, Emmanuel, Piche, Thierry, Guigay, Joel, Francois, Eric, and Guerin, Olivier

Published
2018
Full Text
View/download PDF

15. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Author

Ferris, Robert L., Blumenschein, George, Jr., Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin J., Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Docampo, Lara Carmen Iglesias, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Lynch, Mark, Jayaprakash, Vijayvel, Li, Li, and Gillison, Maura L.

Published
2018
Full Text
View/download PDF

17. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Author

Harrington, Kevin J, Ferris, Robert L, Blumenschein, George, Jr, Colevas, A Dimitrios, Fayette, Jérôme, Licitra, Lisa, Kasper, Stefan, Even, Caroline, Vokes, Everett E, Worden, Francis, Saba, Nabil F, Kiyota, Naomi, Haddad, Robert, Tahara, Makoto, Grünwald, Viktor, Shaw, James W, Monga, Manish, Lynch, Mark, Taylor, Fiona, DeRosa, Michael, Morrissey, Laura, Cocks, Kim, Gillison, Maura L, and Guigay, Joël

Published
2017
Full Text
View/download PDF

18. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

Author

Stephanie, Laetitia, Borbath, Ivan, Castex, Petorin, Caroline, Terrebonne, Eric, Bouhier-Leporrier, Karine, Suc, Etienne, Hautefeuille, Vincent, Bourgeois, Vincent, Cany, Laurent, Dewaele, François, Niccoli, Patricia, Seitz, Jean-François, Lecaille, Cédric, Rebischung, Christine, Rossi, Valérie, Baconnier, Mathieu, Dubreuil, Olivier, Ferec, Marc, Deplanque, Gael, Geslin, Guillaume, Wanicki Caron, Isabelle, Lavau Denes, Sandrine, Bedenne, Laurent, Ligeza, Catherine, Maringe, Eric, Ran-Royo, Anne-Laure, Guigay, Joel, Rougier, Philippe, Walter, T., Tougeron, D., Baudin, E., Le Malicot, K., Lecomte, T., Malka, D., Hentic, O., Manfredi, S., Bonnet, I., Guimbaud, R., Coriat, R., Lepère, C., Desauw, C., Thirot-Bidault, A., Dahan, L., Roquin, G., Aparicio, T., Legoux, J.-L., Lombard-Bohas, C., Scoazec, J.-Y., Lepage, C., and Cadiot, G.

Published
2017
Full Text
View/download PDF

22. Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study

Author

Bozec, Alexandre, Schultz, Philippe, Gal, Jocelyn, Chamorey, Emmanuel, Chateau, Yann, Dassonville, Olivier, Poissonnet, Gilles, Santini, José, Peyrade, Frédéric, Saada, Esma, Guigay, Joël, Benezery, Karen, Leysalle, Axel, Santini, Laure, Giovanni, Antoine, Messaoudi, Lila, and Fakhry, Nicolas

Published
2016
Full Text
View/download PDF

31. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Author

Machiels, Jean-Pascal H, Haddad, Robert I, Fayette, Jérôme, Licitra, Lisa F, Tahara, Makoto, Vermorken, Jan B, Clement, Paul M, Gauler, Thomas, Cupissol, Didier, Grau, Juan José, Guigay, Joël, Caponigro, Francesco, de Castro, Gilberto, Jr, de Souza Viana, Luciano, Keilholz, Ulrich, del Campo, Joseph M, Cong, Xiuyu Julie, Ehrnrooth, Eva, and Cohen, Ezra E W

Published
2015
Full Text
View/download PDF

33. Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors

Author

Bozec, Alexandre, Benezery, Karen, Ettaiche, Marc, Chamorey, Emmanuel, Vandersteen, Clair, Dassonville, Olivier, Poissonnet, Gilles, Riss, Jean-Christophe, Hannoun-Lévi, Jean-Michel, Chand, Marie-Eve, Leysalle, Axel, Saada, Esma, Guigay, Joël, Sudaka, Anne, Demard, François, Santini, José, and Peyrade, Frédéric

Published
2016
Full Text
View/download PDF

35. Targeted therapy-induced radiation recall

Author

Levy, Antonin, Hollebecque, Antoine, Bourgier, Céline, Loriot, Yohann, Guigay, Joël, Robert, Caroline, Delaloge, Suzette, Bahleda, Rastislav, Massard, Christophe, Soria, Jean-Charles, and Deutsch, Eric

Published
2013
Full Text
View/download PDF

47. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Author

Marret, Grégoire, Isambert, Nicolas, Rezai, Keyvan, Gal, Jocelyn, Saada-Bouzid, Esma, Rolland, Frédéric, Chausson, Maggy, Borcoman, Edith, Alt, Marie, Klijanienko, Jerzy, Vansteene, Damien, Guigay, Joël, Kamal, Maud, Bièche, Ivan, and Le Tourneau, Christophe

Subjects
THERAPEUTIC use of monoclonal antibodies, DRUG dosage, CLINICAL trials, HYPERGLYCEMIA, PHOSPHOTRANSFERASES, EPIDERMAL growth factor receptors, ANTINEOPLASTIC agents, CANCER relapse, METASTASIS, HEAD & neck cancer, MONOCLONAL antibodies, TREATMENT effectiveness, DOSE-effect relationship in pharmacology, SQUAMOUS cell carcinoma, DRUG toxicity, CHEMICAL inhibitors
Abstract

Summary: Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. Objective We investigated the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetics, and preliminary efficacy of the combination of copanlisib, an intravenous, pan-class I PI3K inhibitor, with the anti-EGFR monoclonal antibody cetuximab in recurrent and/or metastatic HNSCC patients in a phase I dose-escalation trial. Patients and methods Copanlisib was given intravenously on days 1, 8, and 15 of 28-day cycles at the dose of 45 mg and 30 mg, in combination with standard doses of weekly cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 on days 8, 15, and 22, and weekly thereafter). Results Three patients received copanlisib 45 mg, of whom two experienced grade 3 hyperglycemia during Cycle 1 that met the DLT criteria. Eight patients were then treated with copanlisib at the dose of 30 mg. Because of the occurrence of hyperglycemia, a premedication with metformine was introduced on the day of the injections. No DLTs were reported at this dose level. The trial was stopped early because of the unfavourable toxicity profile of the combination. Among eight evaluable patients for response, four patients (50%) had disease stabilization according to RECIST1.1 as best response. Conclusion Copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent and/or metastatic HNSCC patients. Trial registration NCT02822482, Date of registration: June 2016. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again

Author

Hofman, Paul, Ayache, Nicholas, Barbry, Pascal, Barlaud, Michel, Bel, Audrey, Blancou, Philippe, Checler, Frédéric, Chevillard, Sylvie, Cristofari, Gael, Demory, Mathilde, Esnault, Vincent, Falandry, Claire, Gilson, Eric, Guerin, Olivier, Glaichenhaus, Nicolas, Guigay, Joël, Ilie, Marius, Mari, Bernard, Marquette, Charles-Hugo, Paquis-Flucklinger, Véronique, Prate, Frédéric, Saintigny, Pierre, Seitz-Polsky, Barbara, Skhiri, Taycir, van Obberghen-Schilling, Ellen, Obberghen, Emmanuel, Yvan-Charvet, Laurent, Laboratoire de Pathologie Clinique et Expérimentale. Hôpital Pasteur [Nice], Hôpital Pasteur [Nice] (CHU), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), E-Patient : Images, données & mOdèles pour la médeciNe numériquE (EPIONE), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Laboratoire d'Informatique, Signaux, et Systèmes de Sophia-Antipolis (I3S) / Projet MEDIACODING, Signal, Images et Systèmes (Laboratoire I3S - SIS), Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Centre d’Innovation et d’Usages en Santé (CIUS), Laboratoire de Cancérologie Expérimentale (LCE), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Département de Néphrologie - Hôpital Pasteur [Nice], Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de biologie et modélisation de la cellule (LBMC UMR 5239), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de Cimiez, pôle Gériatrie Gérontologie, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Institut de Biologie Valrose (IBV), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de PhysioMédecine Moléculaire (LP2M), Centre méditerranéen de médecine moléculaire (C3M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Nice, Ligue Departementale des Alpes Maritimes de Lutte contre le Cancer, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Université Côte d'Azur (UCA), and École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)

Subjects
education, research, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, well-being, Perspective, aging, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, cancer, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, optimization, elderly, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation
Abstract

International audience; It is generally accepted that carcinogenesis and aging are two biological processes, which are known to be associated. Notably, the frequency of certain cancers (including lung cancer), increases significantly with the age of patients and there is now a wealth of data showing that multiple mechanisms leading to malignant transformation and to aging are interconnected, defining the so-called common biology of aging and cancer. OncoAge, a consortium launched in 2015, brings together the multidisciplinary expertise of leading public hospital services and academic laboratories to foster the transfer of scientific knowledge rapidly acquired in the fields of cancer biology and aging into innovative medical practice and silver economy development. This is achieved through the development of shared technical platforms (for research on genome stability, (epi)genetics, biobanking, immunology, metabolism, and artificial intelligence), clinical research projects, clinical trials, and education. OncoAge focuses mainly on two pilot pathologies, which benefit from the expertise of several members, namely lung and head and neck cancers. This review outlines the broad strategic directions and key advances of OncoAge and summarizes some of the issues faced by this consortium, as well as the short-and long-term perspectives.

Published
2019
Full Text
View/download PDF

49. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells

Author

Baconnais Sonia, Amiel Corinne, Schneider Véronique, Témam Stéphane, Lang Philippe, Guigay Joël, Vérillaud Benjamin, Klibi Jihène, Bombik Izabela, Gelin Aurore, Gourzones Claire, Jimenez Anne-Sophie, and Busson Pierre

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Nasopharyngeal carcinoma (NPC) is a human epithelial malignancy consistently associated with the Epstein-Barr virus. The viral genome is contained in the nuclei of all malignant cells with abundant transcription of a family of viral microRNAs called BART miRNAs. MicroRNAs are well known intra-cellular regulatory elements of gene expression. In addition, they are often exported in the extra-cellular space and sometimes transferred in recipient cells distinct from the producer cells. Extra-cellular transport of the microRNAs is facilitated by various processes including association with protective proteins and packaging in secreted nanovesicles called exosomes. Presence of microRNAS produced by malignant cells has been reported in the blood and saliva of tumor-bearing patients, especially patients diagnosed with glioblastoma or ovarian carcinoma. In this context, it was decided to investigate extra-cellular release of BART miRNAs by NPC cells and their possible detection in the blood of NPC patients. To address this question, we investigated by quantitative RT-PCR the status of 5 microRNAs from the BART family in exosomes released by NPC cells in vitro as well as in plasma samples from NPC xenografted nude mice and NPC patients. Results We report that the BART miRNAs are released in the extra-cellular space by NPC cells being associated, at least to a large extent, with secreted exosomes. They are detected with a good selectivity in plasma samples from NPC xenografted nude mice as well as NPC patients. Conclusions Viral BART miRNAs are secreted by NPC cells in vitro and in vivo. They have enough stability to diffuse from the tumor site to the peripheral blood. This study provides a basis to explore their potential as a source of novel tumor biomarkers and their possible role in communications between malignant and non-malignant cells.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results